Eliza A. Hawkes

553 St Kilda Rd
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 150 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial Abstracts.

Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial Abstracts.

Journal: JCO oncology practice
Published: May 29, 2026

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

Journal: British journal of haematology
Published: May 28, 2026

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Journal: Leukemia & lymphoma
Published: May 26, 2026

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Journal: European journal of haematology
Published: April 14, 2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Journal: Haematologica
Published: April 12, 2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

Journal: HemaSphere
Published: March 25, 2026

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

Journal: Leukemia & lymphoma
Published: March 17, 2026

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Journal: British journal of haematology
Published: March 11, 2026

Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.

Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.

Journal: NPJ precision oncology
Published: March 02, 2026

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Journal: Blood neoplasia
Published: February 17, 2026
Showing 1-12 of 150

Last Updated: 09/26/2026